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Mechanism of partial agonism in AMPA-type
glutamate receptors
Hector Salazar1,2,*, Clarissa Eibl1,2,*, Miriam Chebli1,2 & Andrew Plested1,2
Neurotransmitters trigger synaptic currents by activating ligand-gated ion channel receptors.
Whereas most neurotransmitters are efﬁcacious agonists, molecules that activate receptors
more weakly—partial agonists—also exist. Whether these partial agonists have weak activity
because they stabilize less active forms, sustain active states for a lesser fraction of the time
or both, remains an open question. Here we describe the crystal structure of an a-amino-
3-hydroxy-5-methyl-4-isoxazolepropionate receptor (AMPAR) ligand binding domain (LBD)
tetramer in complex with the partial agonist 5-ﬂuorowillardiine (FW). We validate this
structure, and others of different geometry, using engineered intersubunit bridges. We
establish an inverse relation between the efﬁcacy of an agonist and its promiscuity to drive
the LBD layer into different conformations. These results suggest that partial agonists of the
AMPAR are weak activators of the receptor because they stabilize multiple non-conducting
conformations, indicating that agonism is a function of both the space and time domains.
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T
he ionotropic glutamate receptor (iGluR) family of ligand-
gated ion channels provides the majority of excitatory
neurotransmission in the central nervous system1. At
synapses throughout the nervous system, activation of AMPARs
(a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors)
plays an essential role in complex thought, as well as processes
such as learning, memory formation and brain development.
Their ubiquity has also led them to be implicated in neuro-
degenerative and psychiatric disorders1–3.
Structures of the full-length AMPA receptor in complex with
different ligands4 provide important details about the architecture
of this receptor family. AMPARs assemble of four subunits5, each
comprising a large extracellular amino-terminal domain (ATD) a
ligand binding domain (LBD) that is connected to the ion
channel forming transmembrane domain (TMD) and a carboxyl-
terminal domain (CTD). Glutamate released from the presynaptic
terminal binds to the LBD of postsynaptic AMPARs, causing
rearrangements that result in ion-channel opening and trans-
duction of electrical signals.
The LBD has a bi-lobate fold, built up by an upper D1 and a
lower D2 domain, with the ligand bound between the two lobes.
In the active conﬁguration, the LBDs dimerize through interac-
tions between D1 domains. Upon binding of glutamate, the two
domains close and envelop the neurotransmitter. This motion
provokes the separation of the D2 domains, connected to the ion
channel, and presumably leads to the opening of the receptor
gate6. Nevertheless, the geometry and dynamics of the activation
mechanism of this receptor remains opaque, not least because in
all structures of the full-length AMPA receptor with agonists to
date, the ion pore was closed, despite several arrangements of the
LBD layer being observed.
One of the most pressing questions concerning ligand
activity at enzymes, receptors and drug targets7–9 concerns the
mechanisms by which full and partial agonists produce different
amplitude responses at equally full occupancies of available
binding sites. Partial agonism can be described by two distinct
classical models. The Monod–Wyman–Changeux (MWC) model
imagines that the partial agonist is weaker in shifting its target to
the active state10, producing different divisions of state occupancy
over time. In contrast the Koshland–Nemethy–Filmer (KNF)
model suggests that the receptors can undergo sequential
non-concerted changes of the structure11, meaning that
different ligands, like partial agonists, induce distinct confor-
mational states, and thus a division over spatial variables, such as
the closure of a clamshell domain. However, these two models are
extremes of more general models, which include hybrid
intermediates12, but that might still be too simpliﬁed because
they do not explicitly include multiple conformations. Methods
reporting both conformational space and activation at once offer
a promising avenue to investigate how these distinct models relate
to activity.
Structural studies on isolated AMPAR LBDs in complex with
agonists (that is, glutamate and willardiines) indicated a
correlation between the cleft closure and the agonist efﬁcacy13.
However, although mutations at the ‘mouth’ of the cleft reduce
glutamate efﬁcacy14,15, this correlation is not entirely reﬂected in
full-length structures16,17. Also, MD simulations18, NMR experi-
ments19,20 and single-molecule FRET analysis21 showed that
partial agonists lead to a variety of clamshell conformations.
Thus, the correlation observed between clamshell closure and
efﬁcacy is not consistent, speaking against clamshell closure as the
sole determinant of the degree of channel activation. In the
context of the tetramer, further degrees of freedom, afforded by
different agonists, could explain the differences in efﬁcacy.
In two recent studies, we identiﬁed two distinct conformations
of the tetrameric LBD layer, associated with partial activation of
the AMPA receptor. The ‘closed angle’ conformation (CA) is
trapped by a crosslink between subunits A and C at position
A665C (ref. 22) and represents an activation intermediate
obtained in subsaturating glutamate. A similar compact form
was subsequently obtained for LBDs fully bound to glutamate23.
Here, we present the crystal structure of the soluble GluA2 LBD
bound to the partial agonist 5-ﬂuorowillardiine (FW) in a
different tetrameric arrangement, which we could conﬁrm with
functional trapping in full-length receptors. In this arrangement,
subunits B and D are found in close apposition, distinct from
previously published structures. Extending our study across four
distinct trapping geometries, and seven bridges in all, we found
an inverse relationship between the efﬁcacy of the agonist and the
number of conformations that the AMPA receptor could adopt.
These data show that the efﬁcacy of AMPA receptor agonists is a
function of both time and conformational space.
Results
Structure of a LBD tetramer in a partially-active state. Several
full-length crystal and cryo-EM structures of iGluRs have been
recently solved. Among them, two crystal structures of GluA2
bound to the partial agonist FW in combination with activating
toxin and positive modulator RR2b (ref. 16) (Fig. 1a) and the
(S)-5-Nitrowillardiine (NW) (ref. 17) (Fig. 1b) have been repor-
ted. Both structures have a closed pore, and are most likely
inactive or pre-active states, consistent with the idea that partial
agonists activate the receptor only for a fraction of the time.
To unravel the mechanism underlying partial agonism we
sought to investigate the intermediate states of AMPA receptor
activation by a combined structural and functional approach.
Therefore, we aimed to elucidate the structure of a tetrameric
soluble LBD (sLBD) in complex with the partial agonist.
Screening across B200 conditions of mutants and different
agonists, we obtained a crystal of the sLBD in complex with FW
(Fig. 1c,d) that diffracted to 1.23Å resolution.
The asymmetric unit harbours one molecule with density for
residues Gly1 to Gly264 and a well-deﬁned positive difference
electron density for FW as seen from the ligand-free calculated
omit-map (Fig. 1c; Supplementary Fig. 1). This allowed us to
position the FW with occupancy of one and a B-factor of 7.0
(compared with a mean B-factor of protein atoms within 4Å of
6.9, Table 1) indicating that the site was saturated with ligand.
Within the crystal packing each FW-bound sLBD (sLBD_FW)
forms a back-to-back active dimer with a symmetry mate, which
further builds up into a physiologically plausible tetramer
(Fig. 1d). The D1 dimeric interface in the presented sLBD_FW
structure was intact and essentially indistinguishable from that of
the apo (ligand free, PDB 4u2p, RMSD 0.5Å)16, antagonist-
bound (DNQX, PDB 4l17, RMSD 0.5Å)22 and agonist-bound
LBDs (Glu RMSD 0.4 Å)23 when aligning the C-alpha atoms of
D1. Intact D1 interfaces indicate that the structure is not related
to desensitization6,24.
Although similar to the previously described closed angle (CA)
(ref. 22) and the tight conformation structure23, some unexpected
features were evident (Fig. 1d). LBD movement is an obvious step
in opening the channel22,25,26, so we measured distances between
the four LBD subunits in the sLBD_FW structure to gain insight
into how FW promotes the partial activity of the AMPA receptor.
The diagonal subunit distance was measured between the Ca
atoms of residue Ala665 on subunits A and C. Interestingly, the
A–C distance increases from the active, fully Glu-bound
sLBD state (PDB 4yu0, 8.3 Å) to the resting ligand-free state
(PDB 4u2p, 12.5 Å), mainly because of the open arrangement
of the dimers (Supplementary Fig. 2). This A–C distance is
similar in the new sLBD_FW structure (13.1 Å), but results from
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a shift of each dimer parallel to the interdimer interface and the
plane of the membrane, and away from the overall axis of two-
fold symmetry. The previously reported CA structure (PDB
4L17) was identiﬁed by functional measurements as an
activation intermediate and is diagonally cross-linked by a
disulﬁde-bond, which drove the shorter A-C distance (5.4 Å)
and compact LBD arrangement. The CA structure got its name
from its relatively closed interdimer angle of 113 relative to the
antagonist-bound full-length structure (PDB 3kg2) (Supple-
mentary Fig. 2). The angle is measured between the vectors
created between Ca atoms of Ala665 on chain A and C and
the Ca of Leu748 on the same subunits23. Considering the
wide angle for full-length receptors in a putative apo state (165)
(ref. 27) and bound by glutamate proposed from CryoEM
studies (181) (ref. 25) (Supplementary Fig. 2), the 120 relative
dimer orientation in the sLBD_FW structure (Fig. 1d) appears
to be most similar to the geometry of an intermediate active
state.
Partial agonists allow a lateral shift of the LBD dimers.
According to our sLBD_FW crystal structure, the parallel shift of
the dimers allows subunits B and D to approach to a surprisingly
close extent (Fig. 1e). To validate this arrangement, we used a
well-characterized metal ion trapping approach22,23,28.
The mutant K434H (termed L2) is predicted to form a four-
membered metal bridge with the native residue H435 (Fig. 1e). By
analogy with previous work, if these histidines approach
sufﬁciently to provide Zn2þ coordination, changes of the
receptor current during and after the partial agonist application
in the presence of Zn2þ might be detected. We reviewed recent
crystal structures of the soluble LBD of GluA2,
including: CA (DNQX-bound, 4l17), Tight (Glu-bound, 4yu0)
and of the full-length GluA2 receptor in the ligand free state (Apo
(4u2p) or bound to NW (4u4f), KA (4u2q), KAþRR2bþ tox
(4u5d), FWþRR2b (4u1y) and FWþRR2bþCII toxin (4u5c)
for their potential to offer trapping at the L2 site. This analysis
indicated that the possibility of the L2 bridge forming is unique to
























Figure 1 | Structure of the GluA2 LBD tetramer bound by FW. (a) Side view of the GluA2-toxin-(R,R)-2b-FW complex (PDB: 4u5c), with the subunits
coloured as follows: A (green), B (red), C (blue) and D (yellow). The Con-Ikot-Ikot toxin is shown in orange and the agonist ﬂuorowillardiine (FW)
and the modulator (R,R)-2b are represented in black and cyan spheres, respectively. (b) The GluA2NW structure (PDB: 4u4f) represented as in a.
The partial agonist nitrowillardiine is coloured in black spheres. (c) Crystal structure of the soluble LBD in complex with FW (sLBD_FW) at 1.23 Å
resolution. Domain 1 (light green) and domain 2 (green) harbour the agonist binding site. The inset shows the positive difference electron density
omit map around FW contoured at 2 sigma. (d) The upper panel shows the tetrameric sLBD_FW structure oriented as in the full-length structures
presented in A and B. FW is shown as black spheres. The relative dimer orientation of 120 is measured by the angle between the centre of mass
between Ala665 and Leu748 of subunits A and C. The lower panel shows the top view (turned 90 along the x-axis) onto the crystal structure
of sLBD_FW, which forms a tetramer with its symmetry mates. (e) In the left panel a cartoon showing the localization of the mutant L2, which was
used to validate the sLBD_FW structure is presented. According to the histidine mutation model based on our sLBD_FW structure (right panel)
the L2 mutant should trap between the subunits B (red) and D (yellow). To probe this interface, a binding site for Zn2þ was introduced by using
the native histidine at position 435 and replacing residue K434 for a histidine. The ﬁctive Zn2þ ion is shown as a green sphere and was manually
placed between the four histidines.
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the sLBD_FW structure (Supplementary Table 1). For example,
the distance between the closest pose of the imidazole nitrogen
atoms of residues His434 and His435 in subunits B & D is more
than 18Å in both the apo (ligand free) and fully active
(glutamate-bound) states, which does not allow trapping
(Fig. 2a,b). In our previous work on glutamate-bound LBDs, we
discriminated between the two different arrangements based on
crystal packing, which we called ‘loose’ and ‘tight’23. In the ‘loose’
conﬁguration, the residues of the mutant L2 are close enough to
form a crosslink, but zinc exposure revealed only a small
inhibition of receptor activation by glutamate, and in the absence
of the desensitization-blocker, cyclothiazide (CTZ). To assess
bridging by Zn2þ over active states speciﬁcally, we added 100 mM
CTZ and activated the L2 mutant with either glutamate or the
partial agonists 5-ﬂuorowillardiine (FW), 5-iodowillardiine (IW),
willardiine (HW) and kainate (KA) (Fig. 2; Supplementary
Fig. 3A). The response of the L2 mutant was not modiﬁed over a
range of glutamate concentrations (10 mM–10mM) in the
presence of Zn2þ , indicating that the L2 crosslink cannot form
when the receptor is glutamate-bound (Fig. 2c). In contrast, after
zinc exposure in the presence of partial agonists, the active
fraction was reduced (Fig. 2d). The most profound trapping was
provoked by FW, which reduced the current elicited by 10mM
glutamate by 30% (Fig. 5), even though there was no discernible
modiﬁcation of the current during zinc exposure. The recovery of
the current after trapping was relatively slow (t¼ 290±30ms)
indicating that this is one of the most stable crosslinks that we
observe (Figs 2d and 5). Furthermore, we compared the extent of
trapping from short (30ms) to long time application (10 s) of
Zn2þ , obtaining a further reduction in the active fraction of only
10% after 3 s of application, indicating that the reaction was
already practically saturated after short intervals (Supplementary
Fig. 3B,C). These striking results show that the sLBD_FW
structure represents a unique arrangement of the LBDs, one that
is available exclusively to partial agonists. Bridging is apparently
neutral with regard to efﬁcacy, and cannot occur for glutamate-
bound AMPA receptors (Fig. 2c).
Partial agonists selectively support diagonal crosslinks. In
functional studies the A665C mutant could be selectively trapped
at concentrations of glutamate close to the EC50 (B500mM), in the
presence of the oxidizing agent copper-phenanthroline (CuPhen).
This crosslink could be observed in the CA tetramer structure22
(Fig. 3a). However, in the sLBD_FW structure, cysteine residues
introduced at position 666 did not form a crosslink (their C-alphas
being too distant at 17Å). We therefore substituted three positions
in the FG-loop (I664, A665 and V666) with cysteine (Fig. 3a). Each
mutant was tested for its crosslinking potential with different
partial agonists as FW, IW, HW and KA under oxidizing
conditions (Fig. 3b). We used a quadruple barrel fast perfusion
system that enables the fast application of each partial agonist in
the presence of CuPhen, and allowed the partial agonist to
dissociate whilst holding the disulﬁde bond with CuPhen before
assessing the active fraction (Supplementary Fig. 4).
Perhaps surprisingly, given the sLBD_FW structure, we
obtained trapping for the mutants I664C, A665C and V666C
with all partial agonists FW, IW and KA (Fig. 3b; Supplementary
Fig. 5A). However, HW failed to trap robustly at the I664C
site (Active fraction 88±10% P¼ 0.0139 versus WT see Fig. 5a).
Receptors were better trapped at this site with the other partial
agonists (active fraction range 77–82%), or at other sites (58–82%
across 11 conditions).
Promiscuous trapping by the weak partial agonist kainate.
Compact packing of the LBDs in the sLBD_FW structure
produces interdimeric interfaces, including lateral subunit inter-
faces (between A & B and C & D) (Fig. 1d). To further validate
this structure as a snapshot of an activation intermediate in full-
length receptors, we used an already existing palette of engineered
binding sites for Zn2þ with distinct expectations of bridging by
zinc, according to the sLBD_FW structure.
Two similar engineered sites, expected to crosslink in the
sLBD_FW arrangement, occur between the D2 lobes of
the subunits A & B or C & D. These sites are formed by the
mutations D668H T672H K761H (termed T1) and D668H
K765H D769 (termed HH)23. We also used a triple histidine
mutant G437H, K439H, D456H (termed HHH), which was
designed to bridge the D1 lobes22 (for positions of the His-
mutants, see Fig. 4a,c). In our FW structure, the distance between
the residues across the lateral divide between dimers (again
between subunits A & B or C & D) is larger than 20Å, leading to
the expectation that cross-linking would not be supported by FW
(Fig. 4c, Supplementary Table 1).
The mutants T1 and HH trap when FW and KA are bound at
high-concentrations of each partial agonist (Fig. 4; Supple-
mentary Fig. 5B), in contrast to GluA2 WT (Fig. 4b). For T1 we
observed a reduction of the active fraction of 24% and 23% for
FW and KA, respectively; while the HH mutant displayed a
reduction of the active fraction of 33% and 31% for FW and KA,
respectively. These results are in agreement with our structural
prediction (Fig. 5b and Supplementary Table 1). These observa-
tions contrast with measurements in the presence of low
concentrations of glutamate, which protected against trapping23
indicating that low occupancy by glutamate is not equivalent to
saturating occupancy by a weak partial agonist (that is, kainate).
Subsequently we extended this scan by analysing two additional
partial agonists, IW and HW, which also showed a substantial
reduction of the active fraction by 19% and 23% for IW and HW,
respectively (Supplementary Fig. 5B). This observation conﬁrms
Table 1 | Data collection and reﬁnement statistics.
GluA2 LBD bound to FW
Data collection
Space group P21212 (#18)
Cell dimensions
a, b, c (Å) 126.47, 44.42, 47.28,
a, b, g () 90.0, 90.0, 90.0
Resolution (Å) 47.28 1.23 (1.30 1.23)*
Rmeas 6.9 (70.0)
I/sI 14.5 (2.3)
Completeness (%) 96.7 (92.8)
Redundancy 4.07
Reﬁnement












Bond lengths (Å) 0.012
Bond angles () 1.492
This structure was determined from one crystal.
*Values in parentheses are for highest-resolution shell.
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the attainment of these interfaces during the receptor activation
with partial agonist.
Finally we used the HHH mutant as a negative control. When
we applied FW, IW and HW at high concentration (1mM for
each partial agonist) in the presence of Zn2þ , we failed to observe
any effect (active fraction range 99–100%; Fig. 4d; Supplementary
Fig. 5b). Strikingly, the active fraction after the application of KA
and Zn2þ showed a reduction of 27±2% (P¼ 0.0145 compared
with wild-type) (Supplementary Fig. 5B). This observation
suggests that the D1 lobes of subunits A & B and C & D would
exclusively come into close proximity in the presence of KA,
which is a poor agonist (efﬁcacy B10% in CTZ, Supplementary
Table 2), compared with the other partial agonists used in this
study, or to glutamate.
Relationship between conformational space and agonism. The
striking failure of FW to promote crosslinking of the HHH
mutant, in contrast with the robust trapping of this mutant in
KA, suggests that the LBD tetramer can explore a larger con-
formational space with KA-bound than it can with FW occupying
all four sites. However, knowing that the unbound LBDs
are conformationally dynamic28 immediately suggested that we
might increase the conformational space available to the receptor
by producing a mixed LBD layer with some subunits bound by
FW and some empty. In other words, intermediate concen-
trations of FW should allow trapping by the HHH bridge, if a
broad sampling of conformational space, and time division of
state occupancy, are both contributing to low activity and
therefore low efﬁcacy of agonists. To investigate this hypothesis,
we explore the reduction of the active fraction after the
application of Zn2þ for the HHH mutant at different concen-
trations of FW. In low and high concentrations of FW there was
no reduction in the active fraction (Fig. 6a). However, the
relationship between the active fraction and log concentration
followed an inverted bell shape, presenting a minimum at 3 mM
(Fig. 6a,b). In agreement with our hypothesis, this result suggests
that trapping at the HHH bridge occurred in states where FW was
bound to some but not all sites. Inhibition was absent for WT
(Fig. 6c).
If we compare the crosslinking proﬁles of KA, willardiines and
glutamate, and we assume that each bridge corresponds to an
exclusive arrangement (or set of arrangements) of the tetramer,
we see that the worse the agonist, the more different conforma-
tions it can visit when the LBD layer is saturated (Fig. 7a). The
lifetime of the bridges bore no relation to the extent of trapping,
indicating that individual states were visited for different fractions
of time (see Fig. 7b and Discussion). We also see that some
bridges are visited in comparatively few tested conditions,
whereas others (like the T1 bridge, which forms laterally between
lobes 2) trap in almost any situation (Fig. 7c). Taken together, the
poor ability of partial agonists to stably close the LBD clamshell
produces increasingly profound conformational promiscuity. In
turn, because some LBD tetramer conformations are ineffective at
opening the channel, an increased propensity to visit different,
inactive arrangements corresponds to worse agonist efﬁcacy
(summarized in Fig. 7d).
Discussion
The ﬁrst crystal structures of the GluA2 LBDs were solved nearly



























































Figure 2 | L2 traps selectively in presence of partial agonists but not in the Apo or the fully active states. (a,b) Left panels show the L2 mutant
models based on the apo (PDB, 4u2p) and the fully active (PDB, 4yu0) structures. The trapping histidines in these models are too distant (distances are
measured between the imidazole N atoms of residues His434 and His435 in subunits B & D) to allow trapping. The right panels show patch clamp
experiments at low concentrations of glutamate of 10mM, testing the Apo state and 10mM, testing the full activated state after the application of CuPhen.
As predicted from the modelled histidines we do not observe changes in the active fraction. (c) Dose–response curves in Glutamate and 100mM CTZ for
WT GluA2 (EC50¼450±70mM) (open circles), the peak current, measured at the beginning of the application of Zn2þ for the mutant L2 (closed circles)
(EC50¼ 350±30mM). Zinc did not modify currents and the active fraction following zinc application (yellow circles) was ﬁt by a linear function (c¼0.99;
n¼4). (d) In the left panel, the L2 mutation modelled into the sLBD_FW structure could allow coordination of a ﬁctive Zn2þ ion (green sphere) by K434H
and H435 from subunits B and D with minimal conformational change. Dashed lines indicate distances between ﬁctive Zn2þ and the imidazole N atoms.
Trapping after the application of 100mM FW and 10mM Zn2þ (left panel) and 1mM KA and 10mM Zn2þ (right panel). Arrows indicate the reduction of
the current after trapping in presence of Zn2þ . Open circles indicate double exponential ﬁts of the recovery after trapping.
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dynamics studies and the latest full-length structures of the
glutamate receptor bound to agonists, antagonists and modula-
tors, LBD movements during activation are not fully understood,
perhaps because of their inherent complexity16,29,30. Nonetheless,
there has been comparatively little testing of which conformations
can be obtained by functional receptors undergoing normal
activation in cell membranes4. By combining crystallographic
studies with engineered binding sites for Zn2þ or cysteine
crosslinks, we could verify trapping of the full-length receptor in
different functional states, assign these states to LBD tetramer
geometries, and compare the properties of trapped receptors to
the overall ensemble activated in a particular condition. Impor-
tantly, by conﬁrming that mutations we made did not alter the
channel opening equilibrium much in the absence of zinc, we
ensured that we worked with receptors that were good mimics of
wild-type receptors, (Supplementary Table 2). Unfortunately,
receptor constructs heavily engineered for crystallization do not
always obey this criterion. Trapping bridges can lock potassium
channels and NMDA receptors into active, open channel
states31,32. Perhaps surprisingly, given these observations, all the
bridges that we have studied to date in the AMPA receptor, either
inhibit activity when they coordinate zinc, or are neutral, as
shown here for some partial agonists23.
Our crystal structure of the soluble LBD in complex with FW
(sLBD_FW) shares similarities with the full-length structures, like
an intact D1 interface and a stabilized interface between subunits
A&B and C&D, which was conﬁrmed by cross linking
experiments. However, a parallel shift of the dimers away from
the pore and in the same plane as the membrane allows novel
interdimer cross-links (L2) between subunits B&D. Further,
we could conﬁrm that the interface HHH between the upper (D1)
lobes of subunits A&B or C&D occurs only in certain
circumstances, such as the presence of saturating KA or
intermediate concentrations of better agonists like FW and
glutamate.
Critically, the effects we see are not related to agonist
afﬁnity, because FW and HW have very different apparent
afﬁnities, despite their similar efﬁcacies, and almost indis-
tinguishable trapping proﬁles (Fig. 7). Recently, it was sugge-
sted that agonist afﬁnity and efﬁcacy might be very tightly
related in nicotinic channels33. However, our data not only
show that this is not the case in AMPA receptors, but provide
an intuitive reason why not. Our measurements were made in
the absence of desensitization and yet agonists with very
different apparent afﬁnities have essentially the same efﬁcacies
(compare HW and FW—94 fold difference in EC50 and 1.1-fold
difference in efﬁcacy) (Supplementary Fig. 6), similar to a
previous report13. Such decoupling, which may be inconsistent
with a strict MWC interpretation, breaks down as soon as
conformational space opens up in distinct ways for different
ligands.
The mutants T1 and HH were both trapped in the presence of
FW (Fig. 5) and the same interface is present in the NW crystal
structure, with a distinct geometry. In the full-length crystal
structures of FW and KA in the presence of the CII toxin the
subunits are more separated. Interestingly, the L2 interface,
between domains 1 of subunits B and D, which conﬁrms the
sLBD_FW structure is adopted in full-length, functional recep-
tors, is not present in any of the recently published full-length
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Figure 3 | Partial agonists trap the A–C interface. (a) Top view of the LBD layer of the CA structure23. Subunits A (green) and C (blue) are covalently
linked by a disulﬁde bond formed between the introduced Cys665 on subunits A and C. The lower panel cartoon shows the localization of the position
A665C. (b) Patch clamp experiments showing test pulses for cysteine mutations on positions 664-666. CTZ (100 mM) was present throughout the whole
experiment. The recovery of the current in 10mM glutamate and DTT following trapping in the presence of CuPhen (10mM) with 5-ﬂuorowillardiine (FW)
(right panel) or Kainate (KA) (left panel) was recorded. Arrows indicate a reduction of the current after trapping, which was observed for I664C, A665C
and V666C but not for wild type (WT, bottom panel). Open circles indicate double exponential ﬁts to the recovery after trapping. The time constants are
summarized in Fig. 5. The difference between the active fraction after trapping in the presence of FW and KA for I664C, A665C and V666C compared with
WT was signiﬁcant for FW (Po0.005) and KA (Po0.05).
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NW (ref. 30) (Fig. 1a,b). Whether the absence to date of
this conformation in full-length structures is because of a
crystallographic bias of catching one state out of many LBD
arrangements, or that it represents a more active conformation
whilst the channel in the structures is closed, will require further
work.
We do not imagine that we have explored the full complement
of arrangements that are available to the LBD tetramer, even
though we have trapped 4 distinct geometries. Rather, it is
fascinating that the pattern of different trapping geometries is so
rich given the stereochemical limits of disulﬁde bonds and
engineered metal bridges. These approaches can only detect
proximity in the sub-nanometre range, and it is clear that open
angles between LBD dimers are readily available30,32 (although
their functional consequences remain unclear). When we take a
step backwards and note that all measurements here were made
in the presence of CTZ to reduce intradimer mobility related to
desensitization, wild-type receptors in synapses likely possess a
truly mind-boggling array of degrees of freedom, which, given the
inhibitory nature of almost all bridges, mostly seem to serve the
object of reducing activity.
Given that multiple subconductance states are available to the
AMPA receptor pore, it seems that time and space division of
activity is a general property that propagates throughout the
receptor. On the other hand, in Cys-loop receptors, single
channel measurements show that partial agonists activate the
same conductance states of the receptor but with a decreased
open probability9. The same scenario is observed in NMDA
receptors34, suggesting that the opening of the gate is an all or
nothing event10, and that partial agonism is a purely time domain
process. These observations are consistent with the MWC idea
that the same conformations (at least, the open or closed channel)
are occupied for different fractions of the time according to
agonist efﬁcacy. If MWC applied to AMPA receptors, we would
expect the same trapping proﬁles, independent of each agonist,
but perhaps with the maximum extent of trapping developing
over different time periods, corresponding to frequent or
infrequent visits to a given state. On the other hand, if a
pure KNF interpretation were correct, we might expect
to see individual arrangements exclusively trapped, for different
agonists. However, neither idea is consistent with our observation
of overlapping sets of arrangements being visited.
Instead, a more general model that includes equilibrium
between multiple arrangements12 is needed to describe our
observations. A broad conformational ensemble may result from
concerted intermediate states, but in the case of the AMPA
receptor, seems more likely to descend from independent
transitions of individual subunits. Numerous observations
support a relation between distinct agonist-dependent confor-
mations of individual subunits and AMPA receptor activity.
Consistent with the multiple conformations that the lobes can
adopt in presence of partial agonists20, twisting motions and
other degrees of freedom have been reported35–37. Also small
changes in the side chain orientations of the D2 lobes in GluA3
receptors bound to partial agonist, might be correlated to
complex modal behaviour of the channel conductance38,39.
Whether kainate and willardiines induce substantial differences
in LBD dynamics remains a complex question35,40, but here we
show that they do induce distinct conformations of the LBD
tetramer layer. Despite considerable study, teasing out a causal
relationship between activity and subunit conformation in full-
length receptors has not been trivial to date. Future work may
investigate how manipulations at the level of individual subunits
with known conformational effects might propagate into altered
tetramer activity.
Given published data13, we had expected to ﬁnd a broad range
of efﬁcacies for willardiine ligands, but in our hands the range was
narrow (30–50% between IW and HW, the largest and smallest
substituents on the 5-position of the willardiine structure).
Indeed, some differences in efﬁcacy are apparent between
expression systems and neurons, perhaps because of differential
glycosylation, the use of particular mutants and auxiliary
subunits. Agonism is in any case very sensitive to geometry of
the LBDs and so the cause of these discrepancies might be hard to
ascertain. Given that we saw a narrow range of efﬁcacies, it
was no surprise that the trapping proﬁles of different willardiine
partial agonists were all similar- except that willardiine prote-
cted against trapping on the I664C bridge, consistent with a
marginally higher efﬁcacy and chiming with the protective effect
of saturating glutamate against formation of the A665C bridge22.
Consistent with a variable partition over distinct conformations
of the LBD tetramer in time, we saw little correlation between the
stability of a given trapped arrangement (inferred from the time



















































Figure 4 | Failure to trap the D1 lateral interface is particular to
saturating FW. (a) Cartoon showing the localization of the mutants in the
LBD layer. The red cross indicates that the HHH mutant is expected not to
trap with FW, whereas the green ticks indicate proximity consistent with
trapping. (b) Wild-type receptors did not show a decrease in the active
fraction after the application of Zn2þ and FW. (c) The mutated residues are
depicted in the sLBD_FW structure. Expected distances between the
histidine imidazole N-atoms and ﬁctive Zn2þ ions (green spheres) are
denoted by dotted lines and expressed in Ångstroms. (d) Patch-clamp
experiment showing the response of the HHH mutant, which was not
modiﬁed in saturating FW. The difference between the active fraction after
trapping in the presence of FW versus WTwas not signiﬁcant (P¼0.5436).
The difference between the active fractions after the trapping of T1 and HH
was induced by FW compared with WTwas signiﬁcant (Po0.009). Arrows
indicate the reduction of the current after trapping. The recovery of current
in 10mM glutamate and EDTA following trapping (ﬁt with double
exponential function, circles) showed a common fast component,
corresponding to the exchange of solution, and a slow component.
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of trapping, which is a convolution of the geometry and the
occupancy (Fig. 7). Therefore, equal time occupancies of given
arrangements are incompatible with our observations.
In summary, by validating LBD trapping mutants, we found
that the less efﬁcacious the agonist is, the more distinct
conformations the AMPA receptor can visit. In other words,
partial agonists are bad at activating the channel because they
allow the LBD to sample conformations that are unproductive.
This observation suggests that partial agonism not only occurs by
the limited ability of a given ligand to close the LBD, but also
because of the (possibly consequent) reduced ability to constrain
LBD movement within the tetramer.
Methods
Protein expression and puriﬁcation. Rat GluA2 ligand binding domain (S1S2
fusion) in pET22b vector was kindly provided by E. Gouaux. The V666C mutation
was introduced by Overlap mutagenesis and sequence veriﬁed by DNA sequencing.
The protein was expressed in Escherichia coli Origami B(DE3) cells with an
N-terminal His8-tag followed by a trypsin and thrombin cleavage site. Protein
expression was induced with 100mM IPTG at an OD600 of 0.9. After 21 h at 20 C,
the cells were harvested by centrifugation at 12,000 g for 20 min, and lysed by the
Avestin EmulsiFlex homogenizer in 20mM Tris HCl, pH 8.0, 150mM NaCl, 5mM
methionine, 1mM glutamate (lysis buffer) supplemented with 5mM MgSO4,
1mM PEFA-Bloc (Roche), 25 mMml 1 DNAse I and 50mMml 1 lysozyme.
The His8-tagged GluA2 LBD containing lysate was clariﬁed by centrifugation at
53,000 g for 50 min and loaded onto 5ml HisTrap HP column (GE Healthcare)
pre-equilibrated in lysis buffer. After successive washing steps with lysis buffer
supplemented with 25mM imidazole, the protein was eluted with an imidazole
gradient from 25 to 500mM. GluA2 LBD containing fractions, as analysed by SDS–
PAGE, were pooled an dialysed overnight at 4 C against 20mM Tris HCl pH 7.4,
200mM NaCl, 5mM methionine, 1mM glutamate, 1mM EDTA, 1mM CaCl2.
Dialysed protein was digested with Trypsin (Sigma) at a molar ratio of 1:100 for 1 h
at room temperature and stopped by the addition of 20mM EDTA and 2mM
PEFA block. After the complete cleavage was conﬁrmed by SDS–PAGE analysis,
the protein was further puriﬁed by size-exclusion chromatography (SEC) using a
Superdex 200 10/300 gel ﬁltration column (GE Healthcare) in SEC buffer, 10mM
HEPES pH 7.0, 150mM NaCl, 1mM ETDA supplemented with 1mM glutamate.
The pooled protein fractions were extensively dialysed against the glutamate-free
SEC buffer to get rid of glutamate. The protein was supplemented with 10mM 5-
ﬂuorowillardiine (FW) and concentrated to 11mgml 1 by a 10 kDa molecular
weight cutoff Amicon ultra centrifugal device (Millipore).
Crystallization and data collection. GluA2 LBD_FW was crystallized at 4 C in
sitting drop using vapour diffusion. The crystal was obtained by mixing 200 ml
protein-FW solution with 200ml precipitant solution (100mM Na/KPO4 pH 6.2,
50.0% v/v PEG 200, 200mM NaCl) using a Gryphon Robot (Art Robbins
Instrument). A disk-like crystal, appearing within three days, was looped and
directly ﬂash-frozen in liquid nitrogen. Diffraction data were collected on beamline





















WT 99 ± 2 3 ± 2 – 95 ± 9 2 ± 1 – 97 ± 1 4 ± 1 – 101 ± 3 5 ± 1 –
I664C 82 ± 2 4 ± 1 208 ± 30 77 ± 2 2 ± 0.5 289 ± 53 88 ± 10 2 ± 1 133 ± 7 79 ± 2 2 ± 0.5 182 ± 50
A665C 72 ± 1 4 ± 1 370 ± 90 74 ± 3 4 ± 1 197 ± 70 80 ± 3 2 ± 0.5 179 ± 38 73 ± 1 3 ± 1 154 ±11
V666C 58 ± 3 5 ± 3 219 ± 30 61 ± 8 6 ± 3 278 ± 82 66 ± 8 2.5 ± 0.5 168 ± 11 62 ± 3 8 ± 4 193 ± 23
Zn/EDTA
WT 98 ± 2 4 ± 1 – 94 ± 4 3 ± 2 – 97 ± 8 5 ± 1 – 98 ± 1 4 ± 1 –
T1 75 ± 3 7 ± 2 224 ± 47 80 ± 4 4 ± 2 239 ± 63 85 ± 2 9 ± 2 119 ± 24 76 ± 1 5 ± 1 101 ± 18
HH 66 ± 3 7 ± 1 163 ± 37 59 ± 3 9 ± 3 97 ± 10 63 ± 2 7 ± 1 156 ± 55 68 ± 3 8 ± 1 163 ± 37
HHH 100 ± 2 – – 99± 2 – – 99 ± 5 – – 73 ± 2 7 ± 2 138 ± 19

































































































Zn/EDTACuPhen/DTT Zn/EDTACuPhen/DTT Zn/ED TACuPhen/DTT Zn/ED TACuPhen/DTT
a
b
Figure 5 | Summary of current recovery after trapping. (a) The reduction of the active fraction and the time constants obtained from the double
exponential ﬁtting to the current during the recuperation after trapping (tfast and tslow) for cysteine mutants (for their locations, see Fig. 3). The fast time
constant corresponds to glutamate activation, and the slow component is assumed to correspond to the breaking of the trapping bridge. (b) Equivalent data
for histidine mutants (for their locations, see Figs 1 and 4). The graphs at the base of each column show the active fraction from all of the mutants versus
the different partial agonist. The row end graphs show the individual mutants versus the different partial agonists. All errors are s.e.m., and for all data
columns, n ¼ 5 patches.
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BL 14.1 at the BESSY II electron-storage ring, Helmholtz Zentrum Berlin fu¨r
Materialien und Energie. Data were processed using XDSapp41.
Phasing and reﬁnement. The GluA2 LBD_FW crystal indexed in space group
P21212 and diffracted to 1.23 Å. The structure was solved by molecular replacement
using Phaser-MR42 from the CCP4 Suite and the GluA2 LDB in complex with
glutamate (PDB 1FTJ, chain A) as a search model43. Iterative cycles of model
building in Coot44 and Phenix45 led to a model of GluA2 LBD_FW with an
Rcryst and Rfree of 12.1 and 14.7, respectively. Rfree was calculated using 5% of the
reﬂections, which we omitted at random from the reﬁnement. The ﬁnal model
includes one molecule in the asymmetric unit (from Gly1 to Gly264). Structure
visualization and analysis were performed in PyMOL. Data collection and
reﬁnement statistics are summarized in Table 1.
Primers and plasmids. The mutants for functional studies were generated by
overlap PCR on the GluA2ﬂip template (GI: 8393475) in the pRK5 vector. The
cDNA encoded a Q at the Q/R editing site. The cysteine mutations at positions 664,
























For each mutant, the entire ampliﬁed cassette was conﬁrmed by double-
stranded DNA sequencing.
Electrophysiology. Wild type and mutant AMPA receptors were expressed
transiently in HEK-293 cells for outside-out patch recording. All patches were
voltage clamped between  30 and  60mV. Currents were ﬁltered at 1–10 kHz
( 3 dB cutoff, 8-pole Bessel) and recorded using Axograph X (Axograph
Scientiﬁc) via an Instrutech ITC-18 interface (HEKA) at 20 kHz sampling rate.
The external solution in all experiments contained 150mM NaCl, 0.1mM
MgCl2, 0.1mM CaCl2, 5mM HEPES, titrated to pH 7.3 with NaOH, to which we
added different drugs. For metal bridging experiments, Zn2þ was included at
10 mM in the external solution. To achieve Zn2þ free conditions, EDTA (10 mM), a
potent Zn2þ chelator (KDZn2þ ¼ 10 16.4 M), was added to the external solution.
CTZ stock solution was prepared in DMSO and added at 100 mM to the external
solution. Drugs were obtained from Tocris Bioscience, Ascent Scientiﬁc or Sigma
Aldrich.
To measure the state dependence of trapping in kainate and other partial
agonists in the presence of Zn2þ , we determined the baseline for activation by
10mM glutamate in the presence of 10 mM EDTA, followed by application of
Zn2þ (10 mM) and the chosen agonist via the third barrel of the perfusion tool, for
1 s. Willardiine agonists unbind relatively slowly GluA2, so following modiﬁcation,
we held the patch in a fourth solution of 10 mM zinc alone, to allow the partial
agonist to unbind but to preserve any bridges that had formed. The appropriate
delay for agonist unbinding was determined for each agonist on wild-type receptors
(Supplementary Fig. 4). In separate experiments, to provoke wild-type and the L2
mutant receptor into distinct proportions of the resting, intermediate and active
states, we co-applied different concentrations of Glu (in the presence of 100 mM
CTZ) with zinc. For all experiments, we quantiﬁed the effect of trapping by
determining the fraction activated by 10mM glutamate in EDTA (10 mM)
immediately after trapping as the active fraction (AF). We assessed the effects
of modiﬁcation by calculating the active fraction AF as follows:
AF ¼ 1 Islow
Ipre
ð1Þ
where Islow was the amplitude of the slow component of the double exponential
ﬁt to the current immediately following CuPhen treatment and Ipre was the
peak current before treatment22. The current was ﬁt with a double exponential. We
took the fast component to be activation by glutamate, and the slow component to
HHH
Active fraction WT 
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100 μM FW
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 10 mM Glu
WT
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Figure 6 | HHH traps at intermediate concentrations of FW. (a) Trapping at different concentrations of FW. Three records from different patches showing
trapping after the application of Zn2þ (10 mM) for 100nM (dark blue), 3mM (orange) and 100 mM FW (light blue). The inset shows the current after
trapping displaying a robust reduction occurring at 3 mM. The ﬁts (dots) are double exponentials ﬁtted to the recovery after trapping the arrows and
symbols indicate measurements plotted in c. (b) Currents from WT GluA2 were not modiﬁed at any concentration of FW. (c) Dose–response curves for
FW in Zn2þ and 100mMCTZ for WTGluA2 (EC50¼ 1.7±0.2 mM) (closed blue circles) and the mutant HHH (closed yellow circles) (EC50¼ 2.7±0.3mM).
The active fraction for WT GluA2 is ﬂat (blue open dots). The active fraction for the HHH mutant (open yellow circles) is ﬁt by a log-normal function with a
maximum inhibition at 3 mM FW. All error bars are s.e.m. (n¼ 5).
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represent the breaking of any bridges that formed. The amplitude of the slow
component was the trapped fraction, and we subtracted this fraction from 1 to get
the active fraction. A log-normal function was ﬁtted to the active fraction of the L2
mutant activated by FW. Disulﬁde crosslinking of cysteine mutants was performed
in a similar way, with patches being modiﬁed by CuPhen (10 mM) instead of Zn2þ ,
and being otherwise held in DTT (1mM) rather than EDTA. Following
modiﬁcation in the presence of willardiines, the patches were held in a CuPhen-
containing solution for agonist to unbinding for the same period as with
experiments with Zn2þ .
We measured concentration–response curves for wild-type and mutant
receptors in the presence of 100 mM CTZ to block desensitization. We obtained the






½An þ ½EC50n ð2Þ
where n is the Hill coefﬁcient, Imax is the maximum response and [A] stands for the
agonist concentration.
All p-values were determined by a nonparametric randomization test (using
Z105 iterations; DCPyPs suite, https://code.google.com/p/dc-pyps/). A paired
randomization test was used, where the same patch was compared between
different conditions. The spread of the data is indicated as s.d. of the mean.
Data availability. The gene GRIA2 (from Rattus Norvegicus) was used in this
work. The coordinates and structure factors for the FW-bound LBD structure were
deposited in the Protein Data Bank (PDB) under accession code 5JEI. The other
data that support the ﬁndings of this study are available from the authors on
reasonable request.
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